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Background: Systemic glucocorticosteroids are side-effect prone but often necessary for the
treatment of severe asthma (SA). Our goal was to assess the usefulness of medical history,
physiological variables and biomarkers as predictors of response to oral steroids.
Methods: After 4 weeks of treatment optimization, 84 patients with SA and 62 with mild-to-
moderate asthma (MA) underwent a 2 week double-blind placebo-controlled oral prednisolone
intervention (0.5 mg/kg BW daily) (NCT00555607).
Results: Responders had a lower FEV1% (73.7 vs 88.0), lower FEV1/FVC ratio (0.65 vs 0.73), lower
quality of life (SGRQ score 39.1 vs 31.4), lower total sputum cell number (1.0 vs 4.5 106) and
higher number of sputum eosinophils (16.8% vs 6.3%) (p< 0.05). For all asthmatics, the degree
of improvement in FEV1 correlated with sputum eosinophils, level of asthma control, FeNO, qual-
ity of life, age of asthma onset and blood eosinophils. In SA, sputum eosinophils 3% (OR 9.91),
FEV1 60% (OR3.7), andSGRQ> 42.2 (OR3.25)wereassociatedwitha good response tooralpred-
nisolone. The highest sensitivity and specificity to predict more than 12% increase in FEV1 in SA
after oral prednisolone was found for sputum eosinophils 3% and FeNO> 45 ppb.
Conclusions: Sputum eosinophils and FeNOwere the best predictors of favorable response to oral
prednisolone in severe asthmatics. A guided approach to glucocorticosteroid treatment should be
recommended as it favors better control of the disease and presumably a lower rate of adverse
events.
The study has been registered at the site: clinicaltrials.gov with number: NCT00555607.
ª 2013 Elsevier Ltd. All rights reserved.for Allergy Research, Karolinska Institutet, IMM Physiology, P.O. Box 287, SE-171 77 Stockholm,
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Abbreviations
ACQ Juniper’s asthma control questionnaire
ASA acetylsalicylic acid
BIOAIR the study of longitudinal assessment of
clinical course and BIOmarkers in Severe
Chronic AIRway disease
BMI body mass index
COPD chronic obstructive pulmonary disease
CRP C-reactive protein
ED emergency department
FeNO fraction of exhaled nitric oxide
FEV1 forced expiratory volume in 1 s
FIV forced inspiratory volume in 1 s
FVC forced vital capacity
ICS inhaled corticosteroids
LABA long-acting b2 agonist
MA mild-to-moderate asthma
NSAID non-steroidal anti-inflammatory drug
OR odds ratio
OST oral steroid treatment
ROC receiver operating characteristic
RR relative risk
Rs Spearman’s rank correlation coefficient
SA severe asthma
SABA short-acting b2 agonist
SGRQ St. George’s respiratory questionnaire
WBC white blood cell count
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Systemic glucocorticosteroids represent a necessary ther-
apeutic option, especially in problematic, severe asthma
and in asthma exacerbations [1e3]. However, use of this
treatment is often limited by significant side effects,
including osteoporosis, arterial hypertension, diabetes,
hypothalamicepituitaryeadrenal axis suppression, obesity,
cataracts, skin thinning and glaucoma [1]. Optimization of
the risk/benefit relationship for systemic glucocorticoste-
roid treatment is vital in the management of patients with
severe asthma.
Asthma is no longer regarded as being a single disease
entity, but instead a syndrome comprised of several patho-
physiological endotypes and clinical phenotypes [4e6]. This
concept is supported by the heterogenous response patterns
observed for asthmamedications, such as those documented
for inhaled corticosteroids [7], b-agonists [8] and leukotriene
receptor antagonists [9,10]. Similarly, the efficacy of sys-
temic glucocorticosteroids is variable as reflected by the
identification of a subgroup of difficult-to-treat or steroid
resistant asthmapatients [11]. The identification of a specific
phenotypeofpatientswhoaremost likely tobenefit fromoral
steroid treatment would improve asthma management. It is
hypothesized that treatment guided by objective predictors
will result in better disease control, a lower rate of adverse
events and diminished health care costs.
The objective of this study was therefore to perform an
in-depth analysis of how patients’ baseline characteristics
influenced their response to a two week oral steroid trial.
One hundred and forty six patients with mild-to-moderate
or severe asthma were included in this investigation that
used medical history, physiological variables and bio-
markers as possible predictors of favorable response. Dif-
ferences in the characteristics of responders and non-
responders to treatment were analyzed, and correlations
between studied variables with the degree of improvement
after oral steroid treatment were examined. The sensitivity
and specificity of the potential predictors of oral steroid
responsiveness were also evaluated.Methods
Study design
Details regarding the BIOAIR study design and methodology
can be found in Ref. [12] and in the on line depository.
Patients with severe asthma (SA) and mild-to-moderate
asthma (MA) were screened and included into the study.
After a four week treatment optimization period an oral
steroid (prednisolone 0.5 mg/kg of body weight/day or
placebo) was added to regular treatment in a double-blind
placebo-controlled manner for two weeks. The study
(clinicaltrials.gov NCT00555607) was approved by the ethics
review board (IRB number: 01-329).
Subjects
Asthma was diagnosed by pulmonary specialists according to
published criteria [1,13]. Patients included in the severe
asthma (SA) group had been under specialist treatment for at
least one year and had experienced at least one exacerba-
tion requiring oral steroid treatment in the past year, despite
continuous treatment with high doses of inhaled cortico-
steroids (ICS; at least 1600 mg/day budesonide or beclome-
thasone, 800 mg/day fluticasone or equivalent), and long-
acting b-agonists, and oral theophylline for at least one
year. Patients in the mild-to-moderate asthma (MA) group
had stable disease and received daily treatment with a
maximum of 800 mg/day budesonide or beclomethasone,
500 mg/day fluticasone or equivalent. The MA patients used
short-acting b-agonists as needed but did not require treat-
ment with long-acting b-agonists and had not experienced
exacerbations or hospitalizations in the past year.
Measurements
Lung function was assessed as forced expiratory volume in
1 s (FEV1), and forced vital capacity (FVC), according to
published guidelines [14,15]. A reversibility test as well as
Phenotypic predictors of response 1523skin prick tests to common aeroallergens were performed
at the screening visit. Induced sputum was obtained using
inclusion and exclusion criteria according to published
recommendations [16]. Fraction of exhaled nitric oxide
(FeNO) was measured using a NIOX analyser (Aerocrine AB,
Solna, Sweden) according to guidelines [17]. All patients
completed the St. George’s respiratory questionnaire
(SGRQ) [18], and the Juniper’s Asthma Control Question-
naire (ACQ) [19].
Data collection and statistical methods
Data was entered into a central database through a web-
based Case Record Form (eCRF) system developed specif-
ically for the BIOAIR study. Patients’ baseline characteris-
tics are expressed as mean standard error of the mean
(SEM). Continuous variables were analyzed by Man-
neWhitney U test and categorical variables by c2 test. The
outcome of treatment was defined as change in FEV1%
predicted (DFEV1Z FEV1% predicted post e FEV1% pre-
dicted pre steroid treatment). Cut-offs DFEV1> 0% and
DFEV1 12% were evaluated as definitions of a favorable
outcome of oral steroid treatment. To identify baseline
characteristics that may predict the outcome of OST, sub-
jects with a positive outcome were compared with those
who did not respond at all to OST. Correlations of studied
variables with degree of improvement in FEV1 after OST
were evaluated with the application of Spearman’s rank
correlation coefficient. The following baseline character-
istics were analyzed: sex, age, reversibility, body mass
index (BMI), sputum eosinophils, sputum neutrophils, bloodTable 1 Demographic data and baseline characteristics of the s
ICS e inhaled corticosteroids, CRP e serum C-reactive protein, at
determined).
Severe asthma
Number of patients (n) 85
Age (y) (minemax) 50.2 ± 1.4 (18e72)
Females (%) 57.1%
FEV1 (% pred) 73.2 ± 2.3
FEV1 (L) 2.08 ± 0.08
FEV1/FVC 0.67 0.01
Reversibility 8.7 0.7
ICS (median [mean ± SD])
beclomethasone eq.
1600 mg [2044 ± 91
OCS (median [mean SD; minemax])
prednisolone eq.
10 mg (14.15 11.8
BMI (kg/m2) 28.3 ± 0.6
QoL (SGRQ) 44.8 ± 2.1
ACQ (Juniper) 2.03 ± 0.1
CRP (mg/L) 5.6 0.8
Atopy (%) 37.6%
FeNO (ppb) 46.9 6.6
Sputum cells (106) 3.36 1.1
Sputum eosinophils (%) 17.9 ± 3.7
Sputum neutrophils (%) 40.4 3.8
Blood eosinophils (108/L) 3.75 0.4
p< 0.05 in bold.
a ManneWhitney U test.
b Chi-square test.eosinophils, smoking history, FeNO, acetylsalicylic acid
(ASA) hypersensitivity, FEV1% predicted, FEV1/FVC, child-
hood onset (<16 years), SGRQ and Juniper ACQ. Odds ratios
(OR) and relative risk (RR) in univariate analysis were
calculated. For numerical variables median, 25 percentile
and 75 percentile as possible cut-off values were evalu-
ated. Chi-square test (or Fisher’s exact test wherever
appropriate) was applied. Multivariate logistic regression
model including all potential predictors with a univariate p
value of less than 0.1 was built and adjusted for atopy, sex,
age and smoking status. Receiver operating characteristic
(ROC) curves were drawn to study sensitivity and specificity
of evaluated variables to predict a good response to OST.
SPSS version 17.0 software (SPSS Inc, Chicago, Ill.) was used
for the statistical analysis. p< 0.05 was considered a sta-
tistically significant difference for all tests.Results
Patients’ baseline characteristics
Demographic data and baseline characteristics of the 151
recruited patients are displayed in Table 1. SA patients
were older than those with MA (50.2 vs 43.4 years), had a
higher BMI (28.3 vs 25.2), and lower lung function (FEV1% of
predicted: 73.2 vs 89.9%) as compared with MA. The SA
group was also characterized by a lower quality of life (44.8
vs 23.2 SGRQ units) and worse asthma control (2.0 vs 1.0
ACQ units). In comparison to MA, sputum eosinophils were
significantly higher in SA patients (5.9% vs 17.9%).tudy cohort [mean values (SEM), unless stated differently].
opy defined as at least one positive skin prick test (ND e not
Mild-to-moderate asthma p
66 ND
43.4 ± 1.6 (21e70) 0.001a
59.7% 0.858b
89.9 ± 2.5 <0.0001a
2.76 ± 0.09 <0.0001a
0.70 0.01 0.093a
10.5 0.7 0.091a
2] 775 mg [606 ± 223] <0.0001a
; 2e50) e ND
25.2 ± 0.5 <0.0001a
23.2 ± 2.2 <0.0001a
1.03 ± 0.7 <0.0001a
4.6 1.2 0.081a
46.9% 1.0b
39.3 4.4 0.957a
1.82 0.3 0.425a
5.9 ± 1.8 0.014a
45.8 4.4 0.433a
3.20 0.4 0.531a
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The oral steroid trial was completed by 146 patients,
including 84 SA and 62 MA subjects. Five patients did not
complete the OST and were excluded from further ana-
lyses. There were no major adverse events reported
during the oral steroid intervention. The OST resulted in
a mean 6.6% increase in FEV1% predicted in SA
(pZ 0.002, steroid treatment vs placebo). No significant
effects of the steroid intervention were observed in
MA (0.47%, pZ 0.38). The oral steroid treatment did
not induce significant changes in the FEV1/FVC ratio in
either of the studied groups. As many as 58.3%
(nZ 49) of the patients with SA were improved
(improvement defined as any degree of increase in FEV1,
DFEV1> 0%) by OST and in 17.8% (nZ 15) of SA
patients, lung function increased by more than 12%
(DFEV1 12%).Table 2 Characteristics table for the whole study population,
sponders DFEV1 12% (mean SEM). QoL e quality of life (St G
protein, ACQ e asthma control questionnaire). ManneWhitney t
ues< 0.05 were considered as statistically significant differences
Asthma group Non-responders
DFEV1< 0%
Responders
DFEV1> 0%
Number of
patients (n)
146 67 79
Severe
asthmatics
(n)
84 35 49
Age (y)
(minemax)
47.5 1.1
(18e72)
46 1.82
(18e72)
49 1.31
(26e69)
Females (%) 57.5 56.7 58.2
FEV1 (% pred) 80.22 1.84 88.0 ± 2.44 73.74 ± 2.5
FEV1/FVC 0.69 0.010 0.73 ± 0.013 0.65 ± 0.015
Reversibility 9.48 0.509 10.01 0.72 9.04 0.71
Atopy (%) 40.4 40.3 41.7
Age of onset 26.78 27.57 26.13
BMI (kg/m2) 27.04 0.407 27.07 0.55 27.01 0.6
QoL (SGRQ) 35.50 1.84 31.41 ± 2.43 39.11 ± 2.7
ACQ (Juniper) 1.59 0.094 1.44 ± 0.12 1.72 0.141
CRP (mg/L) 5.01 0.64 5.05 1.10 4.98 0.742
FeNO (ppb) 44.0 4.16 48.0 8.04 41.71 ± 4.7
Sputum cells
(106)
2.6 0.61 4.49 ± 1.26 1.02 ± 0.20
Sputum
eosinophils
(%)
12.06 2.27 6.28 ± 2.08 16.8 ± 3.6
Sputum
neutrophils
(%)
42.61 2.96 42.84 4.51 42.4 4.0
Blood
eosinophils
(109)
0.35 0.03 0.311 ± 0.043 0.38 0.04
p< 0.05 in bold.
a Chi-square test.Responders’ and non-responders’ characteristics
There were 79 patients in the whole asthma group who
responded with any degree of improvement to OST, 23 who
improved by at least 12% in FEV1, and 67 patients who did
not respond to the treatment (DFEV1< 0%)(Table 2,
Fig. E3).
Responders defined by DFEV1> 0% were characterized
by a lower FEV1% predicted (73.7 vs 88.0), lower FEV1/FVC
ratio (0.65 vs 0.73), lower quality of life (SGRQ score 39.1 vs
31.4), lower number of total sputum cells (1.0 vs 4.5) and
higher percentage of eosinophils in induced sputum (16.8 vs
6.3) as compared with non-responders (Table 2).
Responders defined by DFEV1 12% were also charac-
terized by a lower FEV1% predicted (66.0 vs 88.0), lower
FEV1/FVC ratio (0.6 vs 0.73), lower quality of life (SGRQ
score 44.5 vs 31.4), lower number of total sputum cells (0.8
vs 4.5) and higher percentage of eosinophils in inducednon-responders DFEV1< 0%, responders DFEV1> 0% and re-
eorge’s respiratory questionnaire, CRP e serum c-reactive
est for difference in means unless stated otherwise. p Val-
between groups.
p Value
(responders
DFEV1> 0%
vs non-
responders)
Responders
DFEV1 12%
p Value
(responders
DFEV1 12%
vs non-
responders)
p Value
(responders
DFEV1> 0%
vs responders
DFEV1 12%)
e 23 e e
e 15 e e
0.28 52 2.27
(31e67)
0.97 0.27
0.715a 60.9 0.64a 0.82a
0.0002 66.04 ± 4.3 0.0001 0.148
0.0002 0.6 ± 0.03 0.0002 0.086
0.215 8.29 0.96 0.190 0.694
1.000a 34.8 0.5a 0.5a
0.74 36.71 0.043 0.012
0.631 27.13 1.06 0.781 0.939
0.044 44.5 ± 4.16 0.007 0.293
0.24 2.13 ± 0.23 0.010 0.101
0.59 4.06 1.25 0.7 0.451
0.9 70.86 ± 13.06 0.073 0.014
0.0003 0.77 ± 0.2 0.004 0.947
0.015 29.70 ± 8.31 0.002 0.088
0.95 41.4 7.66 0.86 0.905
0.072 0.50 ± 0.092 0.025 0.205
Figure 2 Correlation between blood and sputum eosinophils
in asthma patients (RsZ 0.5, p< 0.0001).
Figure 1 Correlation of studied variables with degree of improvement of FEV1 after oral steroid treatment. Panel A: sputum
eosinophils (% cells) RsZ 0.41, pZ 0.008; panel B: FeNO (ppb) RsZ 0.32, pZ 0.03.
Phenotypic predictors of response 1525sputum (29.7 vs 6.3) as compared with non-responders
(Table 2). In addition, these more pronounced responders
were also characterized by a later age of onset of the dis-
ease (36.7 vs 27.6) and higher number of eosinophils in
peripheral blood (0.5 vs 0.3  109). Responders defined by
DFEV1 12% also had significantly higher FeNO (70.9 vs
41.7) and a later age of asthma onset (36.7 vs 26.1) as
compared to responders defined by a DFEV1> 0% cut-off.
Correlation of studied variables with degree of
improvement in FEV1
Significant positive correlations were found between the
degree of improvement in FEV1 after the OST with sputum
eosinophils (RsZ 0.41, pZ 0.008), level of asthma control
(ACQ score, RsZ 0.33, pZ 0.005), FeNO (RsZ 0.32,
pZ 0.029), quality of life (SGRQ score, RsZ 0.26,
pZ 0.035), age of onset of the disease (RsZ 0.28,
pZ 0.02) and blood eosinophils (RsZ 0.24, pZ 0.04)
(Fig. 1 and Fig. E1, on-line repository). Significant negative
correlations were found between the degree of improve-
ment in FEV1 after OST with FEV1% predicted (RsZ0.35,
pZ 0.0015) and FEV1/FVC ratio (RsZ0.23, pZ 0.045)
(Fig. E2, on-line depository). No significant correlations
were found for any other evaluated variable (atopy, BMI,
CRP, total sputum cell number and neutrophils in induced
sputum). It should be noted that there was no correlation
between the degree of improvement in FEV1 after OST and
reversibility test (improvement after b2 agonist) at baseline
(RsZ0.02, pZ 0.186). A significant correlation between
blood and sputum eosinophils was found (RsZ 0.5,
p< 0.0001) (Fig. 2).
Univariate analysis
Predictors of response to oral steroid treatment, using the
outcome of DFEV1> 0% for the SA group, include sputum
eosinophils 3% (OR 4.57), FEV1 74% (OR 3.30),
FEV1 60% (OR 3.76) and SGRQ> 42.2 (OR 2.62). Using the
outcome of DFEV1 12% to indicate response to treatment,blood eosinophils> 0.44 109/L (OR 3.72), FeNO> 25 (OR
13.38) and FeNO> 50 (OR 6.94) were statistically significant
(Table 3). For the MA group, using the outcome of
DFEV1> 0%, statistically significant predictors of response
to steroid treatment were blood eosinophils> 0.24 109/L
(OR 3.11) and FEV1/FVC< 0.7 (OR 3.29). Using the outcome
of DFEV1 12%, statistically significant predictors of
response were FEV1 60% (OR 31.20), FEV1/FVC< 0.7 (OR
5.83) and childhood onset (<16 y) (OR 0.07) (Table 3).Multivariate analysis
When adjusted for possible confounding factors (sex, age,
smoking history and atopy) and sorted for the outcome
DFEV1> 0%, multivariate logistic regression models in the
SA group showed that sputum eosinophils 3% (OR 9.91),
sputum eosinophils 2% (OR 8.7), FEV1 60% (OR 3.7),
FEV1 74% (OR 3.7) and SGRQ> 42.2 (OR 3.25) were asso-
ciated with a good response to OST. When the outcome
DFEV1 12% was used, blood eosinophils> 0.44 109/L
(OR 4.7) were statistically significant (Table 3). In the MA
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1526 M. Kupczyk et al.group, multivariate analysis using the outcome of
DFEV1> 0% revealed that blood eosinophils> 0.24 109/L
(OR 3.3) and FEV1/FVC< 0.7 (OR 3.3) were associated with
a good response to OST. Using the outcome of DFEV1 12%
in the MA group showed that FEV1 60% (OR 24.8) was
statistically significant (Table 3).
Sensitivity and specificity of evaluated variables to
predict a good response to OST
To evaluate the possibility of using the studied baseline
characteristics as predictors of response to OST, receiver
operating characteristic (ROC) curves were constructed and
analyzed (selected curves are presented in Fig. 3). Of those
asthma patients with sputum eosinophils 3% at baseline,
68.2% improved after the OST (positive predictive value
68.2%, sensitivity 60.0%, specificity 68.2%) and 28.6%
showed an improvement of at least 12% in FEV1 (positive
predictive value 28.6%, sensitivity 83.3%, specificity 60.7%)
(Table E2, on-line repository). The negative predictive
value of this test suggests that in the vast majority of
asthma patients (94.7%), with baseline sputum eosinophil
numbers below 3%, we cannot expect an improvement in
FEV1 greater than 12% after oral steroid treatment. Having
a baseline FEV1< 80% of predicted and an SGRQ score> 30
also had high predictive value for a good response to oral
steroid treatment (69.6% and 60.9%, respectively) (Table
E2, on-line repository). These variables also show high
negative predictive value (93.3% and 92.9%, respectively).
Of those severe asthma patients with sputum
eosinophils 3% at baseline, 76.2% improved after the OST
(positive predictive value 69.6%, sensitivity 76.2%, speci-
ficity 64.7%) and 30.4% showed an improvement in FEV1 of
at least 12% (positive predictive value 30.4%, sensitivity
87.5%, specificity 50.0%) (Table E2, on-line repository). The
negative predictive value of this test suggests that in the
vast majority of severe asthma patients (93.3%), with
baseline sputum eosinophil numbers below 3%, we cannot
expect an improvement in FEV1 greater than 12% after oral
steroids. A high negative predictive value was found also for
FeNO> 45 ppb. In the majority of SA patients (92.0%) with a
baseline FeNO below 45 ppb, a significant improvement in
FEV1 (>12%) after oral steroids should not be expected
(Table E2, on-line repository).
Discussion
Identifying asthma patients who are most likely to benefit
from oral steroids may have significant practical implica-
tions, as this could optimize the risk to benefit ratio of a
very side-effect prone treatment. This is the first compre-
hensive evaluation of phenotypic predictors of response to
oral glucocorticosteroids in severe asthma. We assessed
several possible predictors of a favorable response
including medical history, physiological variables and bio-
markers. We found that there are significant phenotypic
differences between responders and non-responders to the
OST (oral steroid treatment). Responders are characterized
by a lower lung function (FEV1 and FEV1/FVC ratio), lower
quality of life, lower total sputum cell number and
higher number of sputum eosinophils as compared to
Figure 3 Receiver operating characteristic curves (ROC) for eosinophils in induced sputum (A and C) and FeNO (B and D) as
parameters to predict good response to oral steroid treatment in the whole study group (upper panels) and severe asthmatics
(lower panels).
Phenotypic predictors of response 1527non-responders. Moreover, patients who responded to the
oral steroid treatment with more than a 12% improvement
in FEV1 had significantly higher FeNO levels and later onset
of the disease as compared to those who did not respond so
well to oral steroids. The strongest correlation between the
degree of improvement in lung function after OST was
found for sputum eosinophils. The predictive value of
sputum eosinophils was thereafter confirmed by multivar-
iate modeling, where after adjustment for possible con-
founding factors such as age, sex, atopy and smoking,
sputum eosinophils together with lung function and quality
of life remained strongly associated with a good response to
OST in severe asthmatics.
The usefulness of sputum eosinophils in guiding steroid
therapy in asthma has previously been proposed by several
authors [20e22], however those reports have evaluated the
use of inhaled [21,23] treatment in mild-to-moderate,
rather than severe asthmatics. The few previous studies
of oral steroid use include relatively small numbers of pa-
tients [24,25]. In clinical practice we are able to achieve
good asthma control in the majority of mild-to-moderate
asthmatics with currently available controller medica-
tions, mainly inhaled steroids. This is, however not the casein severe, treatment resistant asthmatics where systemic
steroids or other new biological treatments are necessary.
Thus, our goal was to evaluate predictors of responsiveness
to OST in severe asthma and to our knowledge this is the
first report dealing with this issue. The strength of our study
lies in the prospective, double-blinded study design, and
the involvement of several leading clinical centers which
enabled us to include over 80 carefully phenotyped patients
with well-defined severe asthma. Moreover, the impact of
oral steroids was evaluated on top of the intensive anti-
inflammatory therapy introduced to patients during the
four week treatment optimization phase. In our study we
aimed to evaluate not only biomarkers but also several
phenotypic predictors and physiological variables similar to
those previously investigated in preschool children, where
subjects with specific characteristics showed a more
favorable response to inhaled steroids [26].
A favorable outcome for systemic steroids is sometimes
defined as at least a 15% improvement in FEV1 after 14 days
of treatment with an oral steroid (40 mg/d prednisolone) in
patients who demonstrated more than a 15% improvement
in FEV1 following the use of an inhaled b2 agonist [27]. It is
doubtful if such a definition is appropriate for the subgroup
1528 M. Kupczyk et al.of severe asthmatics, since many of those patients are
characterized by a component of irreversible airway
obstruction, probably due to chronic inflammation and
airway remodeling [27e29]. Moreover, the majority of se-
vere asthma patients do not show a 15% improvement in
FEV1 following the use of an inhaled b2 agonist. We there-
fore decided to evaluate two different levels of favorable
outcome for the OST, namely, any degree of improvement
(>0%), and at least a 12% increase in FEV1. We believe this
approach is more applicable to this particular patient
population and may provide valuable information regarding
treatment options in the severe asthma cohort.
Possible limitations of our study include the duration of
treatment (2 weeks) and the definition of the primary
outcome (change in lung function, FEV1). We have however
justified the short course of oral steroids as this is the most
common approach used in clinical practice for a period of
treatment with systemic glucocorticosteroids [1]. It re-
mains a goal for future studies to assess whether our results
can be generalized to longer treatment periods and the
management of exacerbations. However, our choice of the
shorter treatment duration for this first comprehensive
study of predictors of steroid response did impose re-
strictions regarding selection of the primary study
outcome. Although endpoints such as the number of exac-
erbations, quality of life or asthma control index could be
considered clinically relevant, additional determinants, of
a favorable outcome, a significantly longer duration of
treatment would be necessary to have sufficient power to
detect changes in those variables.
Of interest was the fact that in our severe asthma cohort
the percentage of eosinophils and level of exhaled nitric
oxide were relatively high. This raises the question whether
these asthmatics are compliant with current therapy or
should receive a higher dose of ICS or additional anti-
inflammatory treatment (LTRA) before starting oral ste-
roids. Compliance with treatment regimens is one of the
major challenges in everyday clinical practice, especially
with respect to systemic or inhaled glucocorticosteroids in
asthma patients [30]. We do believe however, that this is
unlikely to pose a problem in the current study. First, high
adherence to the treatment protocol was achieved by the
involvement of highly devoted clinical centers and the
frequent and careful follow-up of included patients. This
was confirmed by a surrogate marker of steroid usage,
namely changes in white blood cell numbers. There was
thus a significant increase in the total number of white cells
and neutrophils and a decrease in numbers of peripheral
and sputum eosinophils in all patients randomized to
receive OST as compared with baseline values.
We found that none of the evaluated patients’ baseline
characteristics, or currently available biomarkers, were
better predictors of steroid responsiveness than determi-
nation of eosinophil numbers in induced sputum. Sputum
eosinophilia allows us to predict a response in lung function
following oral steroid treatment in clinical practice. The
study results show that of those severe asthma patients
with baseline sputum eosinophils 3%, almost 70% will
respond favorably to OST, a prediction with acceptable
sensitivity and specificity (76.2% and 64.7%, respectively).
This is in line with the study of Little et al. [24] who, in a
group of 37 patients with stable, chronic asthma found thatsputum eosinophils 4% had a positive predictive value of
68%, with a sensitivity of 54% and specificity of 90% for an
increase in FEV1 15% after a short course of oral steroids.
In another study, ten Brinke et al. [22] demonstrated that
the vast majority of patients with difficult-to-treat asthma
and persistent eosinophilia in induced sputum responded
well to systemic steroid treatment.
For those subjects in whom sputum induction is not
applicable, other practical approaches may be proposed.
We found a good correlation between blood and sputum
eosinophils (Fig. 2). This has further been confirmed in our
multivariate regression model, as blood eosinophils were
also predictors of good response to oral steroids. Of
particular practical interest is the high negative predictive
value of a low sputum eosinophil number and a moderate
elevation of FeNO. In our study, in the vast majority of the
whole asthma population (more than 95%) and in the ma-
jority of severe asthma patients (more than 90%) who had
baseline sputum eosinophils below 3% or FeNO levels below
45 ppb, there was no significant improvement in lung
function after the OST. Generalizing from these observa-
tions, we would suggest that other treatments (including
new biological agents) should be considered for patients
with low sputum eosinophils and unremarkable FeNO
levels, as apart from inducing adverse events, oral gluco-
corticosteroids would seem to have less potential to
improve lung function.
In conclusion, we found major differences in charac-
teristics between responders and non-responders to oral
glucocorticosteroids among asthma patients. Sputum eo-
sinophils and FeNO represented the most promising options
for predicting a favorable outcome to OST. This is the first
study to document this effect in severe asthmatics. Guided
approaches to oral glucocorticosteroid treatment should be
recommended as this would result in better control of the
disease, help to lower the rate of adverse events and
therefore ultimately diminish health care costs.Funding and conflict of interest
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